Grifols Plans U.S. IPO for Biopharma Business to Cut Debt and Boost Growth
Grifols has approved a U.S. IPO of a minority stake in its Biopharma business.
/ 2 items
Grifols has approved a U.S. IPO of a minority stake in its Biopharma business.
Morgan Stanley downgraded Grifols stock to Equal Weight with a lower €11 price target, citing slowdowns in key products like albumin in China and alpha-1.